AVRICORE HEALTH INC (AVCR.CA) Stock Fundamental Analysis
TSX-V:AVCR - TSX Venture Exchange - CA0545211090 - Common Stock - Currency: CAD
Overall AVCR gets a fundamental rating of 4 out of 10. We evaluated AVCR against 8 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for AVCR as it has an excellent financial health rating, but there are worries on the profitability. AVCR does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year AVCR has reported negative net income.
In the past year AVCR had a positive cash flow from operations.
AVCR had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: AVCR reported negative operating cash flow in multiple years.
1.2 Ratios
AVCR's Return On Assets of -42.76% is fine compared to the rest of the industry. AVCR outperforms 75.00% of its industry peers.
AVCR has a Return On Equity of -46.86%. This is in the better half of the industry: AVCR outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.76% | ||
| ROE | -46.86% | ||
| ROIC | N/A |
ROA(3y)-29.53%
ROA(5y)-86.04%
ROE(3y)-36.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 42.53%, AVCR is doing good in the industry, outperforming 62.50% of the companies in the same industry.
AVCR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AVCR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.52%
GM growth 5Y-2.21%
2. Health
2.1 Basic Checks
AVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVCR has more shares outstanding
Compared to 5 years ago, AVCR has more shares outstanding
AVCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
AVCR has an Altman-Z score of 3.70. This indicates that AVCR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.70, AVCR is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
There is no outstanding debt for AVCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.7 |
ROIC/WACCN/A
WACC8.92%
2.3 Liquidity
A Current Ratio of 7.40 indicates that AVCR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.40, AVCR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 7.38 indicates that AVCR has no problem at all paying its short term obligations.
The Quick ratio of AVCR (7.38) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.4 | ||
| Quick Ratio | 7.38 |
3. Growth
3.1 Past
AVCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -194.29%.
AVCR shows a small growth in Revenue. In the last year, the Revenue has grown by 2.89%.
Measured over the past years, AVCR shows a very strong growth in Revenue. The Revenue has been growing by 170.57% on average per year.
EPS 1Y (TTM)-194.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-147.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y239.04%
Revenue growth 5Y170.57%
Sales Q2Q%-61.39%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than AVCR, based on the Enterprise Value to EBITDA ratio.
AVCR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AVCR is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.22 | ||
| EV/EBITDA | 15.42 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for AVCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:AVCR (6/16/2025, 7:00:00 PM)
0.055
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners10.17%
Ins Owner ChangeN/A
Market Cap5.57M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.36 | ||
| P/FCF | 9.22 | ||
| P/OCF | 6.9 | ||
| P/B | 2.85 | ||
| P/tB | 2.96 | ||
| EV/EBITDA | 15.42 |
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY10.85%
OCF(TTM)0.01
OCFY14.5%
SpS0.04
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.76% | ||
| ROE | -46.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.53% | ||
| FCFM | 14.76% |
ROA(3y)-29.53%
ROA(5y)-86.04%
ROE(3y)-36.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.52%
GM growth 5Y-2.21%
F-Score6
Asset Turnover1.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 53.16% | ||
| Cap/Sales | 4.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 290.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.4 | ||
| Quick Ratio | 7.38 | ||
| Altman-Z | 3.7 |
F-Score6
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)316.46%
Cap/Depr(5y)N/A
Cap/Sales(3y)34.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-194.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-147.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.89%
Revenue growth 3Y239.04%
Revenue growth 5Y170.57%
Sales Q2Q%-61.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y138.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y638.6%
OCF growth 3YN/A
OCF growth 5YN/A